Affinity Proteomics


Affinity Proteomics NY

 

Affinity proteomics describes the use of binding molecules in large-scale and in-depth protein analysis and imaging. It includes the investigation of protein properties such as interactions, modifications, expression patterns in tissues, abundance in body fluids and subcellular localization, as well as binding selectivity. These analyses are important for understanding biological processes and disease pathways, as well as to identify and validate new drug targets and diagnostic markers.

Seven national facilities

The Biobank Profiling facility offers high-throughput and multiplexed immunoassay analysis of body fluids including processing and statistical analysis of data.

The Cell Profiling facility provides high-throughput profiling of protein targets in individual cells using multiplexed immunostaining and fluorescence bioimaging, including automated quantitative image analysis and siRNA integration.

Fluorescence Tissue Profiling facility offers multiplex fluorescence-based analysis of protein expression and distribution in human and animal tissue samples to investigate co-existence of proteins, cellular expression and changes in protein distribution related to disease processes.

Mass Cytometry provides state-of-the art single cell proteomics using mass cytometry (CyTOF), including extensive data analysis support for this novel and advanced technology.

The PLA Proteomics facility employs proximity ligation assays (PLA) for high-performance DNA-assisted protein analyses in cells, tissues and immunoblots.

The Protein and Peptide Arrays facility provides an internationally unique resource for autoimmunity profiling and validation of antibodies using protein microarrays and high-density peptide microarrays.

The Tissue Profiling facility provides streamlined services centered on tissue-based techniques such as tissue microarray production, immunohistochemistry and slide scanning. The facility works with both human and animal samples and handles all steps of tissue processing in a high-throughput manner.


National platform steering group
Henrik Grönberg, Chair (Karolinska Institutet)
Carl Borrebaeck (Lund University)
Maria Lagerström-Fermér (AstraZeneca)
Marene Landström (Umeå University)
Artistidis Moustakas (Uppsala University)
Henrik Zetterberg (University of Gothenburg)
Jacob Odeberg (KTH Royal Institute of Technology)


Platform Directors

Peter Nilsson, Platform Director (KTH Royal Institute of Technology)
Ulf Landegren, Vice Platform Director (Uppsala University)